Tampa, FL — The Obesity Action Coalition (OAC) welcomes today’s announcement from the White House outlining new agreements with pharmaceutical manufacturers to significantly lower the cost of several FDA-approved medications, including those used to treat obesity. Under the new agreements, Medicare beneficiaries will pay a co-pay of just $50 per month, making these life-changing treatments
Read Article

2025 has already been a busy year for the Obesity Action Coalition (OAC), especially in our advocacy work to improve access to obesity care. One of the most significant milestones from 2024 was the Centers for Medicare and Medicaid Services (CMS) Proposed Rule, which would expand coverage for obesity medications under Medicare and Medicaid. With
Read Article

FOR IMMEDIATE RELEASE: 80+ Organizations Urge Trump Administration to Cut Spending & Reward Innovation by Expanding Access to Obesity Medications A Centers for Medicare & Medicaid Services (CMS) Proposed Rule Would Address Outdated Policy Constraints & Expand Access to Innovative Treatments for Obesity Tampa, FL (April 3, 2025) — Today, the Obesity Action Coalition (OAC)
Read Article

by Joe Nadglowski, OAC President and CEO For the past 20 years, the Obesity Action Coalition (OAC) has advocated for evidence-based treatments for the disease of obesity. In 2010, OAC began challenging the FDA to take serious action in approving new medicines for obesity treatment. Fast forward to today, and you see we now have
Read Article

Under current law, Medicare’s prescription drug benefit (Part D) excludes “agents when used for anorexia, weight loss, or weight gain”. This exclusion has prevented Medicare from covering obesity medications and has allowed Medicaid plans to opt out of providing such coverage. For more than a decade, the OAC has pursued both legislative and regulatory pathways
Read Article

Managing your weight and health is a journey, and we understand how frustrating it can be when promising treatments like Wegovy (semaglutide) or Zepbound (tirzepatide) are out of reach. With shortages and high costs, it’s tempting to consider other options, like compounded GLP-1 medications. But here’s why that’s a risky path you should avoid.  The
Read Article